SUSTOL
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting (CINV)
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Trial Timeline
Jul 6, 2022 → Oct 1, 2025
NCT ID
NCT05434663About SUSTOL
SUSTOL is a approved stage product being developed by Heron Therapeutics for Chemotherapy-Induced Nausea and Vomiting (CINV). The current trial status is unknown. This product is registered under clinical trial identifier NCT05434663. Target conditions include Chemotherapy-Induced Nausea and Vomiting (CINV).
What happened to similar drugs?
2 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting (CINV) were approved
Approved (2) Terminated (4) Active (15)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05434663 | Approved | UNKNOWN |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting (CINV)